北京大学肝癌诊断治疗研究中心成立于2011年，由北京大学人民医院肝胆外科主任朱继业教授担任北京大学肝癌诊断治疗研究中心主任。

研究领域：主要是肝癌的临床与基础研究。肝癌的发病机制、肝癌的综合治疗手段、手术技术的创新、术后重症患者的管理、肝癌肝移植术后复发和转移的机制研究等。

依托北京大学人民医院肝胆外科，通过对大量肝癌患者治疗经验的总结和归纳，并且对接受不同治疗手段的肝癌患者预后进行科学研究后，在肝癌的治疗手段和治疗效果上取得了重大的创新和突破，形成了以手术切除为主，其他如射频消融、介入治疗、免疫治疗等为辅的肝癌综合治疗方法。对不同类型的肿瘤选用不同的治疗手段，不仅最大限度保存了剩余肝脏的储备功能而且也保证了肿瘤的有效切除范围，术后患者恢复快，肿瘤复发率低，对这些患者的长期随访显示手术取得了极好的疗效。对于全身状况差不能耐受手术切除的患者还率先开展如肝癌射频消融以及腹腔镜下肝癌切除等微创手术方式，而对于病情危重的终末期肝病患者如肝癌合并肝硬化肝功能衰竭，肝癌切除术后肝内多发转移的病例，通过肝移植手术治疗后取得了良好的疗效。目前，中心有大约每年500例肝切除术，累计已经进行了1000多例肝移植手术。2013年，被评为国家外科重点学科。2014年，肝胆外科实验室被评为北京市肝硬化和肝癌基础研究重点实验室。我们与克利夫兰医院、密歇根大学医院、明尼苏达大学医院等顶级医院有着紧密的联系。

机构负责人：朱继业

联系人：高杰

邮箱：gandanwk@vip.sina.com

电话：88324175

地址：北京市西城区西直门南大街11号

Peking University Research Center for Diagnosis & Treatment of Liver Cancer

Peking University Research Center for Diagnosis & Treatment of Liver Cancer was founded in 2011 by Professor Zhu Jiye of Peking University as director of the Department of hepatobiliary surgery of Peking University People's Hospital.

Research areas: mainly the clinical and basic research of liver cancer. The pathogenesis of hepatocellular carcinoma, the comprehensive treatment of liver cancer, the innovation of surgical techniques, the management of severe patients after operation, the mechanism of recurrence and metastasis after liver cancer transplantation and so on.

Institutions: Relying on the Department of hepatobiliary surgery of the Peking University People's Hospital, through a large number of patients with liver cancer treatment experience summary and induction, and the prognosis of patients with hepatocellular carcinoma receiving different treatment methods for scientific research, in the treatment and the therapeutic effect of liver cancer has made a great innovation and breakthrough, formed mainly by surgical operation such as radiofrequency ablation for hepatocellular carcinoma treatment method interventional therapy and immune therapy, supplemented by. Choose different treatments for different types of cancer, not only to maximize the preservation of residual liver reserve function but also to ensure the effective range of tumor resection, postoperative patients recover quickly, tumor recurrence rate is low, the long-term follow-up of these patients showed very good curative effect of surgery achieved. For the poor body condition was not amenable to surgery patients to carry out such as radiofrequency ablation and laparoscopic hepatectomy and minimally invasive surgery, and for critically ill patients with end-stage liver diseases such as liver cirrhosis with liver failure, liver resection after multiple liver metastases, through liver transplantation after treatment achieved good effect. Currenctly, we had about 500 cases of liver resection per year. We have carried out more than 1000 cases liver transplantation so far In 2013, the department has been entitled as the national key discipline of surgery. In 2014, the hepatobiliary surgery laboratory has been entitled as Beijing key research lab of liver cirrhosis and liver cancer basis research. We had tight connections with top hospital such as Cleveland Clinic, University of Michigan hospital, University of Minnesota hospital and so on.

Director：ZHU jiye

Contect：GAO jie

Email：gandanwk@vip.sina.com

TEL：88324175